Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
50 studies found for:    ARSENIC ACID
Hide Display Options

Display Options

Study Details
Participant Details
Identifiers
Dates
Rank Status Study
1 Completed Assessing the Effectiveness of a Water Filter Technology as an Arsenic Mitigation Strategy in West Bengal
Conditions: Total Urinary Arsenic;   Total Arsenic in Water;   Diarrhoeal Disease
Intervention: Device: Pureit As+ Filter
2 Terminated
Has Results
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
Condition: Acute Myelogenous Leukemia
Interventions: Drug: Arsenic Trioxide (ATO);   Drug: Ascorbic Acid
3 Completed
Has Results
Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Decitabine, Arsenic Trioxide and Ascorbic Acid
4 Terminated Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis
Conditions: Essential Thrombocythemia;   Polycythemia Vera;   Primary Myelofibrosis
Interventions: Drug: Arsenic Trioxide;   Dietary Supplement: Ascorbic Acid;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
5 Recruiting Combined Retinoic Acid,Arsenic Trioxide and Chemo for Newly-diagnosed APL
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: ATRA+arsenic;   Drug: ATRA+chemo
6 Terminated Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes
Condition: Myelodysplastic Syndromes
Intervention: Drug: ATO + Ascorbic acid
7 Terminated Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma
Condition: Multiple Myeloma
Intervention: Drug: Arsenic Trioxide, Ascorbic Acid and Bortezomib
8 Completed
Has Results
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
Conditions: Multiple Myeloma;   Stem Cell Transplantation
Interventions: Drug: Arsenic Trioxide;   Drug: Melphalan;   Drug: Ascorbic Acid
9 Terminated Arsenic Trioxide, Thalidomide, Dexamethasone, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: dexamethasone;   Drug: thalidomide
10 Completed All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: All-Trans Retinoic Acid (ATRA);   Drug: Arsenic Trioxide (ATO);   Drug: Idarubicin
11 Unknown  Effects of Folic Acid Supplementation on Arsenic Lowering
Conditions: Arsenic Poisoning;   Toxic Effect of Arsenic and Its Compounds
Intervention: Drug: folic acid supplementation
12 Completed Arsenic Trioxide Plus Vitamin C in Treating Patients With Recurrent or Refractory Multiple Myeloma
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide
13 Completed Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: bortezomib;   Drug: dexamethasone;   Drug: thalidomide;   Drug: Aspirin
14 Completed Folic Acid and Creatine as Therapeutic Approaches for Lowering Blood Arsenic
Condition: High Blood Arsenic Due to Chronic Arsenic Exposure
Interventions: Other: Placebo;   Dietary Supplement: folic acid;   Dietary Supplement: creatine;   Dietary Supplement: creatine + folic acid
15 Completed Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndromes and Acute Myeloid Leukemia
Condition: Myelodysplastic Syndromes and Leukemia, Myeloid, Acute
Interventions: Drug: Arsenic Trioxide;   Drug: Decitabine
16 Completed Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder
Conditions: Chronic Myeloproliferative Disorders;   Leukemia;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases
Interventions: Dietary Supplement: ascorbic acid;   Drug: arsenic trioxide;   Drug: dexamethasone;   Drug: thalidomide
17 Withdrawn Melphalan, Arsenic Trioxide, and Ascorbic Acid in Treating Patients With Relapsed or Refractory Multiple Myeloma
Conditions: Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Refractory Plasma Cell Neoplasm
Interventions: Drug: arsenic trioxide;   Drug: ascorbic acid;   Drug: melphalan;   Procedure: chemosensitization/potentiation;   Procedure: chemotherapy
18 Withdrawn Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Treating Patients With Multiple Myeloma
Conditions: Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma;   Refractory Plasma Cell Neoplasm
Interventions: Drug: arsenic trioxide;   Drug: ascorbic acid;   Drug: dexamethasone;   Drug: thalidomide;   Procedure: anti-cytokine therapy;   Procedure: antiangiogenesis therapy;   Procedure: biological therapy;   Procedure: chemotherapy;   Procedure: drug resistance inhibition;   Procedure: growth factor antagonist therapy;   Procedure: non-specific immune-modulator therapy
19 Completed Effect of Spirulina on Zinc, Vitamin E and Linoleic Acid Levels in Palm Skin Following Chronic Exposure to Arsenic
Condition: Arsenical Keratosis
Intervention: Dietary Supplement: Spirulina
20 Completed
Has Results
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
Condition: Myeloma
Interventions: Drug: Trisenox (Arsenic Trioxide);   Drug: Velcade (Bortezomib);   Drug: Melphalan;   Drug: Vitamin C (Ascorbic Acid)

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.